Crinetics (CRNX)’ paltusotine was granted FDA orphan designation status as a treatment of carcinoid syndrome, according to a post to the agency’s website.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Optimistic Growth Outlook for Crinetics Pharmaceuticals Amidst Strategic Advances and Strong Financial Position
- Crinetics Pharma’s Earnings Call: Positive Outlook Amid Challenges
- Crinetics Pharmaceuticals: Strong Financial Position and Promising Pipeline Drive Buy Rating
- Buy Rating Affirmed for Crinetics Pharmaceuticals: Promising Phase 3 Trial of Atumelnant for CAH
- Crinetics Pharmaceuticals Reports Q1 2025 Financial Results